CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01%
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CureVac NV
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Cash & Cash Equivalents
€402.5m
CAGR 3-Years
-33%
CAGR 5-Years
80%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Cash & Cash Equivalents
€11.7B
CAGR 3-Years
113%
CAGR 5-Years
95%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Cash & Cash Equivalents
€131.3m
CAGR 3-Years
6%
CAGR 5-Years
22%
CAGR 10-Years
11%
Immatics NV
NASDAQ:IMTX
Cash & Cash Equivalents
€218.5m
CAGR 3-Years
2%
CAGR 5-Years
194%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Cash & Cash Equivalents
€24.7m
CAGR 3-Years
-32%
CAGR 5-Years
-18%
CAGR 10-Years
-11%
Formycon AG
XETRA:FYB
Cash & Cash Equivalents
€27m
CAGR 3-Years
-14%
CAGR 5-Years
30%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Cash & Cash Equivalents?
Cash & Cash Equivalents
402.5m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Cash & Cash Equivalents amounts to 402.5m EUR.

What is CureVac NV's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
80%

Over the last year, the Cash & Cash Equivalents growth was -19%. The average annual Cash & Cash Equivalents growth rates for CureVac NV have been -33% over the past three years , 80% over the past five years .

Back to Top